A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

NCT01544114 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis (JIA)

Interventions

DRUG: VIMOVO 250/20
DRUG: VIMOVO 375/20
DRUG: VIMOVO 500/20

Sponsor

Amgen